ClinicalTrials.gg
Not yet recruitingNCT07730047Updated Jul 28, 2026

NLR, ELR and SII Index as Biomarkers of Asthma Control

An observational study in Asthma Control, sponsored by Shaimaa Ali Mohammed. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Shaimaa Ali Mohammed · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
140
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Asthma with a site in Egypt — 10 open to participants now, 11 under way, 1 of them phase 3. Asthma · Egypt.

Planned enrollment
8th of 17
140 · median 137
Started
2026
with 3 others
Observational
17 of 42
5 open now
Primary completion
2027-01
later than 8 of 10 live
Registered
40th of 42
by date

Among the 42 studies in Asthma with a site in Egypt, this one is the 8th largest by planned enrollment of the 17 observational ones that give a count, is one of 4 that started in 2026, is one of 17 observational ones, reaches primary completion later than 8 of the 10 other live ones, and was the 40th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

10 of the 42 studies in Asthma with a site in Egypt are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Asthma with a site in Egypt, or all of them as a file.
02

Study summary

This is Case control study aims to study Neutrophil-to-Lymphocyte Ratio (NLR), Eosinophil-to-Lymphocyte Ratio (ELR), and Systemic Immune Inflammation (SII) Index as Biomarkers of Asthma Controlin adult patients with bronchial asthma.

This study will investigate the association between these inflammatory indices and the level of asthma control to assess their potential value as simple ,readily available and cost -effective biomarkers in clinical practice.

Read the detailed description

Asthma is a chronic condition, mainly characterized by airway inflammation and hyperresponsiveness. Access to effective treatment allows asthma to be well controlled in most patients. However, a large percentage of patients do not attain adequate asthma control despite optimal therapy. Inadequately controlled patients are at high risk of severe exacerbations and death.

Asthma control test (ACT) is a useful clinical method to quantify asthma control status, and it includes a questionnaire about manifestation, medications use, and personal reporting of asthma control.

Neutrophilic, eosinophilic, paucigranulocytic or mixed granulocytic types are four various endotypes of asthma depending on cell counts of peripheral blood, sputum or bronchoalveolar fluid. Neutrophilic inflammations have been studied to be associated with a poor asthma control. In addition to persistent asthma symptoms and atopy, they have been reported to be associated with the presence of eosinophilic inflammation in asthmatic patients.

The systemic immune-inflammation index (SII) is a novel inflammatory marker, with scarce research reporting on the correlation between SII and asthma and asthma-related events The aim of the work is to study Neutrophil-to-Lymphocyte Ratio (NLR), Eosinophil-to-Lymphocyte Ratio (ELR), and Systemic Immune Inflammation (SII) Index as Biomarkers of Asthma Control This is Case control study that will be carried out at chest department, Assiut University Hospital.

It includes • Adult patients aged > 18 years.

  • Confirmed diagnosis of bronchial asthma according to Global Initiative for Asthma (GINA) guidelines.
  • Patients who provided informed consent to participate in the study Excluded from the study• Patients with chronic respiratory diseases other than asthma. • Acute respiratory infection within the previous 4 weeks.
  • Patients with hypertension, diabetes, coronary artery disease, liver and kidney diseases.
  • Patients with hematological disorders, malignancies, autoimmune diseases, or systemic inflammatory conditions that might affect blood cell counts.
  • Patients taking systemic steroids, experiencing acute asthma attack (because infection may affect neutrophil level).
  • Pregnant women. Patients with bronchial asthma will undergo Clinical Assessment Detailed medical history including age, sex, smoking status, duration of asthma, current medications, history of exacerbations, emergency visits, and hospital admissions, followed by complete clinical examination.

Assessment of Asthma Control Asthma control will be assessed using the Asthma Control Test (ACT). ACT was done by asking patients with asthma to complete five questions according to manifestations of asthma, use of relievers, and the effect of the disease on their lives. Scores range from 5 to 25. A total score of 25 is considered as a well control, the level between 20 and 24 is a partial, control whereas a level of 19 and below is a poor control.(9) Laboratory Investigations Venous blood samples will be collected for CBC including neutrophil, lymphocyte, eosinophil, and platelet counts. NLR, ELR, and SII will be calculated.

03

Conditions studied

  • Asthma Control

Browse trials for

Keywords

  • Asthma
  • Neutrophil to Lymphocyte Ratio
  • Eosinophil to Lymphocyte Ratio
  • Systemic Immune- Inflammation Index
  • Asthma Control Test
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of 140 adults: 70 patients with physician-diagnosed asthma and 70 age- and sex-matched healthy controls recruited from the Chest Department of Assiut University Hospital during the study period

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged > 18 years.
  • Confirmed diagnosis of bronchial asthma according to Global Initiative for Asthma (GINA) guidelines.
  • Patients who provided to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with chronic respiratory diseases other than asthma.
  • Acute respiratory infection within the previous 4 weeks.
  • Patients with hematological disorders, , diseases, or systemic inflammatory conditions that might affect blood cell counts.
  • Patients taking systemic , experiencing acute asthma attack (because infection may affect neutrophil level).
  • Pregnant women.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
140 participants (estimated)
Patient registry
No

Groups and cohorts

  • Asthma patients

    patients with physician- diagnosed asthma

    Other: Complete blood count

  • Healthy control

    Healthy volunteers without asthma

    Other: Complete blood count

Interventions

  • OtherComplete blood count

    Venous blood samples will be collected for CBC including neutrophil, lymphocyte, eosinophil, and platelet counts. NLR, ELR, and SII will be calculated

06

What researchers measure

Primary outcomes

  1. Asthma Control Test (ACT) score.

    Asthma control will be assessed using the Asthma Control Test (ACT; score range 5-25 points) at baseline. The ACT score will be analyzed for its correlation with neutrophil-to-lymphocyte ratio (NLR), eosinophil-to-lymphocyte ratio (ELR), and systemic immune-inflammation index (SII).

    Time frame: Baseline (day 1)

Secondary outcomes

  1. Comparison of the accuracy of NLR, ELR, and SII to determine the most reliable biomarker for asthma control assessment.

    To compare the diagnostic performance of NLR, ELR, and SII in distinguishing controlled from uncontrolled asthma and to identify the biomarker with the highest predictive accuracy.

    Time frame: Baseline(day 1)

07

Study locations

1 site
  • Chest Department,Assiut University Hospital
    Asyut, Asyut Governorate 71515, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jan 2027, 5 months later.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 5 months is below that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 28, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Jan 1, 2027
CompletionEst.
Feb 1, 2027
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07730047
Lead sponsor
Shaimaa Ali Mohammed
Responsible party
Shaimaa Ali Mohammed (principal Investigator, Assiut University) — Sponsor-investigator
First posted
Jul 28, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Jul 28, 2026

Study contacts

Shaimaa A Mohammed, MD
Contact
drshimaalimohammed@gmail.com
00201016599093
Shaimaa A Mohammed, MD
principal investigator · Chest Department,Faculty of Medicine,Assiut University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion